News Column

Data from Goethe-University Advance Knowledge in Hepatocellular Carcinoma (Biodegradable human serum albumin nanoparticles as contrast agents for the...

July 29, 2014



Data from Goethe-University Advance Knowledge in Hepatocellular Carcinoma (Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging)

By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Digestive System Diseases and Conditions are presented in a new report. According to news originating from Frankfurt, Germany, by NewsRx correspondents, research stated, "Tumor visualization by magnetic resonance imaging (MRI) and nanoparticle-based contrast agents may improve the imaging of solid tumors such as hepatocellular carcinoma (HCC). In particular, human serum albumin (HSA) nanoparticles appear to be a suitable carrier due to their safety and feasibility of functionalization."

Our news journalists obtained a quote from the research from Goethe-University, "In the present study HSA nanoparticles were conjugated with gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) using carbodiimide chemistry. The nanoparticles had a uniform spherical shape and a diameter of 235 +/- 19 nm. For better optical visualization in vitro and in vivo, the HSA-Gd nanoparticles were additionally labeled with rhodamine 123. As shown by confocal microscopy and flow cytometry analysis, the fluorescent nanoparticles were readily taken up by Huh-7 hepatocellular carcinoma cells."

According to the news editors, the research concluded: "After 24 h incubation in blood serum, less than 5% of the Gd(III) was released from the particles, which suggests that this nanoparticulate system may be stable in vivo and, therefore, may serve as potentially safe T1 MRI contrast agent for MRI of hepatocellular carcinoma."

For more information on this research see: Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):132-141. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)

The news correspondents report that additional information may be obtained from W. Watcharin, Goethe Univ Frankfurt, Inst Inorgan & Analyt Chem, D-60054 Frankfurt, Germany. Additional authors for this research include C. Schmithals, T. Pleli, V. Koberle, H. Korkusuz, F. Huebner, S. Zeuzem, H.W. Korf, T.J. Vogl, C. Rittmeyer, A. Terfort, A. Piiper, S. Gelperina and J. Kreuter (see also Digestive System Diseases and Conditions).

Keywords for this news article include: Frankfurt, Germany, Europe, Acute-Phase Proteins, Blood Proteins, Digestive System Diseases and Conditions, Emerging Technologies, Hepatocellular Carcinoma, Nanoparticle, Nanotechnology, Oncology, Serum Albumin

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters